BioLineRx to Report Second Quarter 2025 Results on August 14, 2025
BioLineRx (NASDAQ: BLRX), a development stage biopharmaceutical company focused on oncology and rare diseases, will release its Q2 2025 financial results on August 14, 2025, before U.S. markets open.
The company will host a conference call at 8:30 a.m. EDT featuring CEO Philip Serlin. Investors can access the call through U.S. dial-in (+1-888-281-1167) or international dial-in (+972-3-918-0685). A live webcast and replay will be available on the company's website, with the call replay accessible until August 16, 2025.
BioLineRx (NASDAQ: BLRX), un'azienda biofarmaceutica in fase di sviluppo focalizzata sull'oncologia e le malattie rare, pubblicher脿 i suoi risultati finanziari del secondo trimestre 2025 il 14 agosto 2025, prima dell'apertura dei mercati statunitensi.
L'azienda terr脿 una conference call alle 8:30 a.m. EDT con la partecipazione del CEO Philip Serlin. Gli investitori potranno partecipare alla chiamata tramite numero statunitense (+1-888-281-1167) o internazionale (+972-3-918-0685). Una diretta webcast e la registrazione saranno disponibili sul sito web della societ脿, con la possibilit脿 di riascoltare la chiamata fino al 16 agosto 2025.
BioLineRx (NASDAQ: BLRX), una compa帽铆a biofarmac茅utica en etapa de desarrollo enfocada en oncolog铆a y enfermedades raras, publicar谩 sus resultados financieros del segundo trimestre de 2025 el 14 de agosto de 2025, antes de la apertura de los mercados estadounidenses.
La empresa realizar谩 una conferencia telef贸nica a las 8:30 a.m. EDT con el CEO Philip Serlin. Los inversores podr谩n acceder a la llamada a trav茅s de los n煤meros de Estados Unidos (+1-888-281-1167) o internacionales (+972-3-918-0685). Habr谩 una transmisi贸n en vivo y una repetici贸n disponible en el sitio web de la compa帽铆a, con la grabaci贸n accesible hasta el 16 de agosto de 2025.
BioLineRx (NASDAQ: BLRX)電� 膦呾枒頃� 氚� 頋穩 歆堩櫂鞐� 欷戩爯鞚� 霊� 臧滊皽 雼硠鞚� 靸濍獏瓿淀暀 須岇偓搿�, 2025雲� 2攵勱赴 鞛 瓴瓣臣毳� 2025雲� 8鞗� 14鞚� 氙戈淡 鞁滌灔 臧滌灔 鞝勳棎 氚滍憸頃� 鞓堨爼鞛呺媹雼�.
須岇偓電� CEO 頃勲 靹るΠ鞚� 彀胳劃頃橂姅 霃欕秬 響滌鞁� 鞓れ爠 8鞁� 30攵�鞐� 旎嵓霟办姢 旖滌潉 歆勴枆頃╇媹雼�. 韴瀽鞛愲摛鞚� 氙戈淡 雮� 鞝勴檾氩堩樃 (+1-888-281-1167) 霕愲姅 甑牅 鞝勴檾氩堩樃 (+972-3-918-0685)毳� 韱淀暣 彀胳棳頃� 靾� 鞛堨姷雼堧嫟. 靸濎瓿� 鞗轨簮鞀ろ姼鞕� 雲鬼檾氤胳潃 須岇偓 鞗轨偓鞚错姼鞐愳劀 鞝滉车霅橂┌, 雲鬼檾氤胳潃 2025雲� 8鞗� 16鞚�旯岇 鞁滌箔 臧�電ロ暕雼堧嫟.
BioLineRx (NASDAQ : BLRX), une soci茅t茅 biopharmaceutique en phase de d茅veloppement sp茅cialis茅e en oncologie et maladies rares, publiera ses r茅sultats financiers du deuxi猫me trimestre 2025 le 14 ao没t 2025, avant l'ouverture des march茅s am茅ricains.
La soci茅t茅 tiendra une conf茅rence t茅l茅phonique 脿 8h30 EDT anim茅e par le PDG Philip Serlin. Les investisseurs pourront acc茅der 脿 l'appel via les num茅ros am茅ricains (+1-888-281-1167) ou internationaux (+972-3-918-0685). Un webcast en direct et un replay seront disponibles sur le site web de la soci茅t茅, avec un acc猫s au replay jusqu'au 16 ao没t 2025.
BioLineRx (NASDAQ: BLRX), ein biopharmazeutisches Unternehmen in der Entwicklungsphase mit Schwerpunkt auf Onkologie und seltenen Krankheiten, wird seine Finanzergebnisse f眉r das 2. Quartal 2025 am 14. August 2025 vor 脰ffnung der US-M盲rkte ver枚ffentlichen.
Das Unternehmen wird eine Telefonkonferenz um 8:30 Uhr EDT mit CEO Philip Serlin veranstalten. Investoren k枚nnen 眉ber die US-Einwahlnummer (+1-888-281-1167) oder die internationale Einwahlnummer (+972-3-918-0685) teilnehmen. Ein Live-Webcast und eine Aufzeichnung sind auf der Website des Unternehmens verf眉gbar, wobei die Aufzeichnung bis zum 16. August 2025 abrufbar ist.
- None.
- None.
Management to Hold Conference Call at 8:30 a.m. EDT
The Company will host a conference call at 8:30 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer.
To access the conference call, please dial +1-888-281-1167 from the
About BioLineRx
BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The Company's first approved product is APHEXDA庐 (motixafortide), with an indication in the
Learn more about who we are, what we do, and how we do it at鈥� or on鈥�.
CONTACTS:
Irina Koffler
LifeSci Advisors, LLC
[email protected]
Moran Meir
LifeSci Advisors, LLC
[email protected]
Logo: https://mma.prnewswire.com/media/2154863/BioLineRx_Ltd_Logo.jpg
听
View original content:
SOURCE BioLineRx Ltd.
FAQ
When will BioLineRx (BLRX) report Q2 2025 earnings?
What time is the BioLineRx Q2 2025 earnings conference call?
How can investors access the BioLineRx Q2 2025 earnings call?
Who will present during the BioLineRx Q2 2025 earnings call?
Until when will the BioLineRx Q2 2025 earnings call replay be available?
